200189-97-5

200189-97-5 structure

Name: CGP 3466B maleate
Chemical Name: N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine,(Z)-but-2-enedioic acid
CAS Number: 200189-97-5
Molecular Formula: C₂₃H₂₁NO₅
Molecular Weight: 391.41700
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2016-12-27 18:27:58
Modify Date: 2024-01-03 02:57:30
Omigapil maleate (CGP3446B maleate) is an orally bioavailable apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD)[1]. Omigapil maleate, a GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that Omigapil maleate has the potential for the research of Alzheimer's disease[2].

Name	N-(benzo[b][1]benzoxepin-5-ylmethyl)-N-methylprop-2-yn-1-amine,(Z)-but-2-enedioic acid
Synonyms	JHW 007 hydrochloride Omigapil maleate Dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine maleate TCH-346 CGP 3466B UNII-3Q69BFZ4OP N-(Dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-(2-propynyl)amine monomaleic acid salt

Description	Omigapil maleate (CGP3446B maleate) is an orally bioavailable apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD)[1]. Omigapil maleate, a GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice, suggesting that Omigapil maleate has the potential for the research of Alzheimer's disease[2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
Target	Apoptosis[2]
In Vivo	Treatment of mice with Omigapil (0.1 mg/kg) results in improved muscle regeneration and increased force[1]. Animal Model: 12-week-old dyW/ mag mice[1] Dosage: 0.1 mg/kg Administration: For the first week of drug treatment, administered once daily by intraperitoneal injection. After weaning (3 weeks of age), applied once daily by oral gavage. Result: Reduced the muscle fibre loss. Many of the functional parameters were significantly improved by omigapil.
References	[1]. Sarina Meinen, et al. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med. 2011 Aug;3(8):465-79. [2]. Tanusree Sen, et al. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β. Sci Signal. 2018 Mar 20;11(522):eaao6765.